Leading doctors and scientists from around the world will gather in Shanghai, China at the end of October for the Advanced Cell Therapy Shanghai Summit, or ACTSS 2018, produced by Phacilitate and ACTSS. The event will showcase advanced therapy medicinal products (ATMPs) with discussion across the development cycle, from research to manufacturing and market access.
The decision to hold the event at the Kerry Hotel Pudong in Shanghai from Oct. 29-31 comes as access to infrastructure and investment in advanced therapies have opened in China, creating opportunities there in the industry, ACTSS and Phacilitate said.
“With a rapidly growing scientific infrastructure in China, the global community needs a global gathering like ACTSS to learn about the emergence of incredible manufacturing capability, investment and high quality research,” said Cindy Ru, Managing Director of CRC Oncology Corp., and Chair of Advisory Board of ACTSS. “Our event creates opportunities for Chinese investors to meet Western companies and for Western companies to learn more about working in China.:
Attendees at ACTSS 2018 will explore developments in global regulations in cell and gene therapy, discuss critical insights into cGMP manufacturing best practices and next generation technologies and their potential to shape the autologous CAR-T landscape in the next 3-5 years, the hosts said.
More than 70 speakers will participate. A full agenda can be found at: http://www.actss2018.org.